Do you want to link to this External Website and leave


Amgen Europe takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Our Approach to Access and Affordability

Why We Do What We Do

Amgen’s mission is to serve patients. Every day, we work to discover, develop and deliver medicines that make a difference to patients’ lives and address some of society’s most serious diseases, including cancer, osteoporosis, and cardiovascular disease.

Healthcare systems are facing unprecedented challenges, such as increasing prevalence of chronic diseases, health disparities and the deployment of healthcare budgets.

At Amgen, we believe that innovative medicines are the best hope for patients in the fight against serious disease. To realize the full value of our medicines and for the patients who need them most, Amgen is delivering integrated patient access and health system solutions.

Delivering Patient Access and Health Systems Solutions

We’re helping to evolve the health ecosystem by actively engaging with and leveraging the strengths of governments, manufacturers, academics, payers, digital health companies, and practitioners. Together, we are working to co-create solutions that transform health systems by not only treating disease after it strikes, but also helping to predict and prevent disease before it occurs.

Amgen is delivering integrated patient access and health system solutions across three pillars and a range of “Amgen Solutions.” Click on each pillar below to learn more about what we’re doing.

The Burden of Disease Dictates Innovation

The growing burden of disease not only takes an enormous human toll, but also creates a huge financial burden on society. Innovation is necessary now, more than ever, to prevent taking a step backward in the progress of human health. For many diseases, better, more effective therapies are needed—key examples are cancer, cardiovascular disease, and osteoporosis.


COVID-19 has highlighted the importance of the prevention and treatment of chronic conditions – such as heart disease and obesity – in reducing the harm attributed to widespread disease outbreaks. The pandemic has also demonstrated how disruptions in care can impede delivery of timely medical attention for urgent and, in many cases, preventable conditions. For more information on how Amgen is supporting patients and communities during the pandemic, visit our COVID-19 Information Center.

Risk of Not Innovating

CARDIOVASCULAR disease is the number one cause of death in Europe with 3.9 million deaths every year and a cost of around €210 billion (1). More than two in five patients who have had a cardiovascular (CV) event will have another within two years (2). A recent study looked at where we might go from here and presents a very stark choice.

As this chart3 shows, if innovation stagnates, the CV mortality rate is predicted to significantly increase. However, if innovations are widely adopted and new innovations come along behind them, the CV mortality rate could be significantly reduced, building on the remarkable gains of the past 50 years. It is important to remember that these lines on this chart represent people's lives—that is what’s at stake here.


Historical data and chart adapted from Ortendahl JD, Diamant AL, Toth PP, Cherepanov D, Harmon AL, Broder MS. Protecting the gains: What changes are needed to prevent a reversal of the downward cardiovascular disease mortality trend? Clinical Cardiology. 2019;42:47-55.

There is a tremendous opportunity—and an urgent need—to bend the curve of cardiovascular disease, cancer, osteoporosis and the many other serious diseases that affect tens of millions of people around the world. Our aspiration is to be a leader advancing innovative medicines that reduce the rising burden of disease to benefit patients, society and other stakeholders.

Oversight of our Approach to Pricing, Access and Affordability of Medicines

In Europe, Amgen monitors its pricing approaches regularly and in accordance with country-specific guidelines and our European Pricing Committee receives regular updates during the year regarding our approach to pricing, access and affordability of our medicines, as well as our philanthropic activities that provide access to our medicines across the globe.

Our Compliance with Drug Pricing Laws

One of our core Company values is “Be Ethical,” and part of being ethical is being compliant. At Amgen, compliance is adhering to the laws and regulations that govern what we do, including those that govern healthcare pricing and reimbursement.


  1. Accessed 21 December 2020
  2. Punekar RS, Fox KM, Richhariya A, et al. Burden of first and recurrent cardiovascular events among patients with hyperlipidemia. Clin Cardiol. 2015;38:483-491.
  3. Sources: 1. Heart Disease and Stroke Statistical Update Fact Sheet. The American Heart Association. 2020. 2. RTI International. Projections of Cardiovascular Disease Prevalence and Costs: 2015–2035: Technical Report [report prepared for the American Heart Association]. Research Triangle Park, NC: RTI International; November 2016. RTI project number 021480.003.001.001.